English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Treatment of latent tuberculosis infection (LTBI) has a critical importance in the control and elimination of tuberculosis (TB) in the United States of America. In 2011, the Centers for Disease Control and Prevention (CDC) recommended the use of a directly observed therapy (DOT) regimen (HP) including the once-weekly use of isoniazid-rifapentine in a period of 12 weeks in pediatric patients aged ≥ 12 years and in patients with HIV (1).

Update of the Recommendations for the Use of Once-Weekly Isoniazid-Rifapentine Regimen to Latent Mycobaterium tuberculosis Infection